Maria Stepanova

17.4k total citations · 9 hit papers
295 papers, 12.7k citations indexed

About

Maria Stepanova is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Maria Stepanova has authored 295 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Epidemiology, 191 papers in Hepatology and 35 papers in Surgery. Recurrent topics in Maria Stepanova's work include Liver Disease Diagnosis and Treatment (192 papers), Hepatitis C virus research (121 papers) and Liver Disease and Transplantation (87 papers). Maria Stepanova is often cited by papers focused on Liver Disease Diagnosis and Treatment (192 papers), Hepatitis C virus research (121 papers) and Liver Disease and Transplantation (87 papers). Maria Stepanova collaborates with scholars based in United States, Russia and United Kingdom. Maria Stepanova's co-authors include Zobair M. Younossi, Linda Henry, Youssef Younossi, Nila Rafiq, Sharon Hunt, Zachary Goodman, Fatema Nader, Manirath Srishord, Andrei Racila and Alita Mishra and has published in prestigious journals such as SHILAP Revista de lepidopterología, Applied Physics Letters and Gastroenterology.

In The Last Decade

Maria Stepanova

277 papers receiving 12.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

2016 916 citations Zobair M. Younossi, Linda Henry et al. profile →
Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008

2011 863 citations Zobair M. Younossi, Maria Stepanova et al. profile →
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

2018 603 citations Zobair M. Younossi, Maria Stepanova et al. profile →
Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality

2011 461 citations Zobair M. Younossi, Maria Stepanova et al. profile →
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States

2012 431 citations Zobair M. Younossi, Maria Stepanova et al. profile →
Epidemiology of chronic liver diseases in the USA in the past three decades

2019 387 citations Zobair M. Younossi, Maria Stepanova et al. profile →
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States

2020 373 citations Zobair M. Younossi, Maria Stepanova et al. profile →
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease

2024 156 citations Zobair M. Younossi, James M. Paik et al. Journal of Hepatology profile →
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease

2023 71 citations Zobair M. Younossi, Maria Stepanova et al. Hepatology Communications profile →

Peers

Countries citing papers authored by Maria Stepanova

Since Specialization

Citations

This map shows the geographic impact of Maria Stepanova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Stepanova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Stepanova more than expected).

Fields of papers citing papers by Maria Stepanova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Stepanova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Stepanova. The network helps show where Maria Stepanova may publish in the future.

Co-authorship network of co-authors of Maria Stepanova

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Stepanova. A scholar is included among the top collaborators of Maria Stepanova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Stepanova. Maria Stepanova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis 2026 ·Hepatology Communications ·(unknown), (unknown), Dominic Labriola, Rebecca Taub, Andrei Racila, (unknown), Maria Stepanova	0
2	Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments 2025 ·Gastro Hep Advances ·Zobair M. Younossi, Maria Stepanova, (unknown), (unknown), Dominic Labriola, Rebecca Taub, Fatema Nader	0
3	Chemical Modification of Nanocrystalline Cellulose for Manufacturing of Osteoconductive Composite Materials 2024 ·Polymers ·(unknown), Maria Stepanova, А. В. Добродумов, И. В. Гофман, Yu. A. Nashchekina, А. В. Нащекин, Evgenia Korzhikova‐Vlakh	4
4	Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region 2024 ·Annals of Hepatology ·Saleh A. Alqahtani, Yusuf Yılmaz, Mohamed El‐Kassas, Khalid Alswat, (unknown), Faisal M. Sanai, (unknown), Saad Alghamdi, Waleed Al-hamoudi, Fatema Nader, Maria Stepanova, Zobair M. Younossi	6
5	Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease breakdown → 2024 ·Journal of Hepatology ·Zobair M. Younossi, James M. Paik, Maria Stepanova, Janus P. Ong, Saleh A. Alqahtani, Linda Henry	156
6	Clinical and patient‐reported outcomes in patients with chronic hepatitis B and C and non‐alcoholic fatty liver disease from real‐world practices in Saudi Arabia, Turkey and Egypt 2024 ·Journal of Viral Hepatitis ·Saleh A. Alqahtani, Yusuf Yılmaz, Mohamed El‐Kassas, Khalid Alswat, Faisal M. Sanai, (unknown), Faisal Abaalkhail, (unknown), Waleed K. Al‐Hamoudi, Fatema Nader, Maria Stepanova, Zobair M. Younossi	4
7	Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease 2023 ·Clinics in Liver Disease ·Maria Stepanova, Linda Henry, Zobair M. Younossi	24
8	Polypeptide-Based Systems: From Synthesis to Application in Drug Delivery 2023 ·Pharmaceutics ·Maria Stepanova, (unknown), Tatiana Tennikova, Evgenia Korzhikova‐Vlakh	15
9	The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease 2023 ·Alimentary Pharmacology & Therapeutics ·Zobair M. Younossi, Maria Stepanova, Sean Felix, Thomas L. Jeffers, Elena Younossi, Zachary Goodman, Andrei Racila, Brian Lam, Linda Henry	3
10	How long is too long: A retrospective study evaluating the impact of the duration of noninvasive oxygenation support strategies (high flow nasal cannula & BiPAP) on mortality in invasive mechanically ventilated patients with COVID-19 2023 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Brian Lam, Maria Stepanova, Linda Henry, Christopher S. King, Mehul Desai	2
11	The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease breakdown → 2023 ·Hepatology Communications ·Zobair M. Younossi, Maria Stepanova, Reem Q. Al Shabeeb, Katherine Eberly, (unknown), Veronica Nguyen, Janus P. Ong, Linda Henry, Saleh A. Alqahtani	71
12	Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system 2022 ·PLoS ONE ·Brian Lam, Maria Stepanova, Chapy Venkatesan, (unknown), (unknown), (unknown), (unknown), Mehul J. Desai, Andrei Racila, (unknown), Linda Henry, Lynn H. Gerber, Zobair M. Younossi	5
13	The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry 2022 ·Hepatology Communications ·Zobair M. Younossi, Yusuf Yılmaz, Mohamed El‐Kassas, Ajay Duseja, Saeed Hamid, Gamal Esmat, Nahúm Méndez‐Sánchez, Wah‐Kheong Chan, Ashwani K. Singal, Brian Lam, Sean Felix, Elena Younossi, Manisha Verma, Jillian Kallman Price, Fatema Nader, Issah Younossi, Andrei Racila, Maria Stepanova	3
14	Clinical effectiveness of nutrof total supplement for Dry age-related macular Degeneration 2018 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Maria Stepanova	2
15	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health‐related quality of life in East Asian patients with hepatitis C virus infection 2018 ·Journal of Viral Hepatitis ·Zobair M. Younossi, Maria Stepanova, Linda Henry, Kwang‐Hyub Han, Sang Hoon Ahn, Young‐Suk Lim, Wan‐Long Chuang, Jia‐Horng Kao, Kinh Van Nguyen, Ching‐Lung Lai, Henry Lik‐Yuen Chan, Lai Wei	14
16	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes 2017 ·Clinical Infectious Diseases ·Zobair M. Younossi, Maria Stepanova, Tarik Asselah, Graham R. Foster, Keyur Patel, Norbert Bräu, Mark G. Swain, Tram T. Tran, Rafael Esteban, M. Colombo, Stephen Pianko, Linda Henry, Marc Bourlière	18
17	Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin 2017 ·Journal of Viral Hepatitis ·Zobair M. Younossi, Maria Stepanova, (unknown), Stéfan Wirth, Philip Rosenthal, Regino P. González‐Peralta, Karen F. Murray, Linda Henry, Sharon Hunt	19
18	Association of work productivity with clinical and patient‐reported factors in patients infected with hepatitis C virus 2016 ·Journal of Viral Hepatitis ·Zobair M. Younossi, Maria Stepanova, Linda Henry, Issah Younossi, Ali A. Weinstein, Fatema Nader, Sharon Hunt	30
19	The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study 2015 ·Liver International ·Zobair M. Younossi, Maria Stepanova, Stanislas Pol, Jean–Pierre Bronowicki, Patrizia Carrieri, Marc Bourlière	45
20	The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life 2015 ·Alimentary Pharmacology & Therapeutics ·Zobair M. Younossi, Maria Stepanova, Fatema Nader, Brian Lam, Sharon Hunt	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact